Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 5
1997 1
1998 5
1999 4
2000 2
2001 4
2002 9
2003 6
2004 8
2005 5
2006 6
2007 4
2008 3
2009 7
2010 13
2011 5
2012 7
2013 7
2014 8
2015 8
2016 11
2017 16
2018 14
2019 14
2020 22
2021 24
2022 20
2023 13
2024 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

237 results

Results by year

Filters applied: . Clear all
Page 1
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, Gerrits D, Geven EJW, Sam J, Lang S, Bommer E, Steinhart V, Husar E, Colombetti S, Van Puijenbroek E, Neubauer M, Cline JM, Garg PK, Dugan G, Cavallo F, Acuna G, Charo J, Teichgräber V, Evers S, Boerman OC, Bacac M, Moessner E, Umaña P, Klein C. Waldhauer I, et al. Among authors: van puijenbroek e. MAbs. 2021 Jan-Dec;13(1):1913791. doi: 10.1080/19420862.2021.1913791. MAbs. 2021. PMID: 33974508 Free PMC article.
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P. Mössner E, et al. Among authors: van puijenbroek e. Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1. Blood. 2010. PMID: 20194898 Free PMC article.
Mirtazapine-induced arthralgia.
Passier A, van Puijenbroek E. Passier A, et al. Among authors: van puijenbroek e. Br J Clin Pharmacol. 2005 Nov;60(5):570-2. doi: 10.1111/j.1365-2125.2005.02481.x. Br J Clin Pharmacol. 2005. PMID: 16236049 Free PMC article. Review.
B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans.
Wang AA, Luessi F, Neziraj T, Pössnecker E, Zuo M, Engel S, Hanuscheck N, Florescu A, Bugbee E, Ma XI, Rana F, Lee D, Ward LA, Kuhle J, Himbert J, Schraad M, van Puijenbroek E, Klein C, Urich E, Ramaglia V, Pröbstel AK, Zipp F, Gommerman JL. Wang AA, et al. Among authors: van puijenbroek e. Sci Transl Med. 2024 Mar 6;16(737):eadi0295. doi: 10.1126/scitranslmed.adi0295. Epub 2024 Mar 6. Sci Transl Med. 2024. PMID: 38446903
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Klein C, et al. Among authors: van puijenbroek e. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. Oncoimmunology. 2017. PMID: 28405498 Free PMC article.
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.
Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Norén GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. Fusaroli M, et al. Among authors: van puijenbroek e. Drug Saf. 2024 Jun;47(6):585-599. doi: 10.1007/s40264-024-01423-7. Epub 2024 May 7. Drug Saf. 2024. PMID: 38713347 Free PMC article.
Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis.
Raschi E, Salvo F, Bate A, De Ponti F, Poluzzi E, Tuccori M, van Puijenbroek E, Joshi N, Khouri C. Raschi E, et al. Among authors: van puijenbroek e. Drug Saf. 2024 Jul;47(7):601-605. doi: 10.1007/s40264-024-01419-3. Epub 2024 Mar 18. Drug Saf. 2024. PMID: 38498258 No abstract available.
How could employing the patient perspective transform pharmacovigilance?
van den Bemt PMLA, van Puijenbroek EP, van Hunsel FPAM. van den Bemt PMLA, et al. Among authors: van puijenbroek ep. Expert Opin Drug Saf. 2024 Jul;23(7):793-796. doi: 10.1080/14740338.2024.2373905. Epub 2024 Jul 3. Expert Opin Drug Saf. 2024. PMID: 38922349 No abstract available.
237 results